Tag: Herceptin
Herceptin (trastuzumab): A monoclonal antibody used to treat HER2/neu overexpressing (HER2+) breast cancer. Herceptin works by binding to the HER2/neu receptor, thereby reducing the effects of overexpression of HER2.
Articles
News
05/01/16
Six-month delay in starting Herceptin linked to reduced survival in HER2+ breast cancer 05/23/15
Sulforaphane inhibits Herceptin-resistant Her2+ tumor growth and reduces triple negative breast cancer stem cell populations 07/22/12
Inflammation can contribute to resistance to Herceptin 05/13/12
A story of long-term stage IV HER2+ breast cancer survival 04/19/12
Green tea polyphenol EGCG slows development of tamoxifen resistance 12/13/11
Metformin improves survival of diabetic women with HER2+ breast cancer 12/01/11
Herceptin plus anthracycline chemotherapy greatly increases risk of heart damage 10/06/11
Non-anthracycline chemotherapy plus Herceptin is effective treatment for HER2+ breast cancer 09/22/11
Herceptin has reduced locoregional recurrence for HER2+ compared to triple negative breast cancer 03/19/11
Treatment with Herceptin for one year improves survival in women with HER2+ breast cancer 11/28/10
Erythropoietin for anemia may hinder Herceptin treatment for HER2-positive breast cancer 11/08/10
Response to neoadjuvant chemotherapy depends on dosage and tumor type 09/09/10
Flaxseed enhances Herceptin treatment in mouse model of HER2 breast cancer
Studies
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database Lisinopril or Carvedilol for Prevention of Trastuzumab Induced Cardiotoxicity Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2 Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients Association between tobacco and alcohol consumption, HER2 polymorphisms and response to trastuzumab in HER2-positive breast cancer patients Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Induction of G2M Arrest by Flavokawain A, A Kava Chalcone, Increases the Responsiveness of HER2 Overexpressing Breast Cancer Cells to Herceptin Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer Prophylactic beta blockade preserves left ventricular ejection fraction in HER2-overexpresssing breast cancer patients receiving trastuzumab: Primary results of the MANTICORE randomized controlled trial Changes in Tumor Expression of HER2 and Hormone Receptors Status after Neoadjuvant Chemotherapy in 21,755 Patients from the Japanese Breast Cancer Registry Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474) Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells Calpain-1 is associated with adverse relapse free survival in breast cancer: a confirmatory study The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study Use of trastuzumab for HER2-positive metastatic breast cancer in daily practice: a population-based study focusing on the elderly Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab Alteration of gene expression in MDA-MB-453 breast cancer cell line in response to continuous exposure to Trastuzumab High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer α-linolenic acid and docosahexaenoic acid, alone and combined with trastuzumab, reduce HER2-overexpressing breast cancer cell growth but differentially regulate HER2 signaling pathways Therapeutic effects of luteolin against progestin-dependent breast cancer involves induction of apoptosis, and suppression of both stem-cell-like cells and angiogenesis Cardiac Surveillance Findings During Adjuvant and Palliative Trastuzumab Therapy in Patients with Breast Cancer Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab Racial differences in outcomes for patients with metastatic breast cancer by disease subtype Natural product sulforaphane selectively inhibits breast cancer stem cells in basal and trastuzumab resistant Her2+ breast cancer Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment? Pathological response and circulating tumor cell count identifies treated HER2 inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2‑positive breast cancer cells in vitro and in vivo Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01) Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Locoregional Recurrence and Survival Outcomes by Type of Local Therapy and Trastuzumab Use Among Women with Node-Negative, HER2-Positive Breast Cancer Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based study Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer Trastuzumab-related cardiac events in the treatment of early breast cancer Alcohol and HER2 Polymorphisms as Risk Factor for Cardiotoxicity in Breast Cancer Treated with Trastuzumab Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831 Factors Predicting Trastuzumab-related Cardiotoxicity in a Real-world Population of Women with HER2+ Breast Cancer Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer Dietary Flaxseed-Trastuzumab Interactive Effects on the Growth of HER2-Overexpressing Human Breast Tumors (BT-474) The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of rel AFRICAN AMERICAN RACE IS A CORRELATE OF HEART FAILURE IN BREAST CANCER SURVIVORS: A STUDY OF 26,347 WOMEN IDENTIFIED WITH BREAST CANCER FROM 1973-2007 Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab Successful Treatment of Trastuzumab-Resistant HER2-Positive Breast Cancer with Extensive Liver Metastases Using the Combination of Trastuzumab and Capecitabine - A Case Report Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic Breast Cancer In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab 3, 3′-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab Docosahexanoic Acid Improves Chemotherapy Efficacy by Inducing CD95 Translocation to Lipid Rafts in ER− Breast Cancer Cells Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study Pertuzumab: new hope for patients with HER2-positive breast cancer Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study Concomitant targeting of tumor cells and induction of T cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer Trastuzumab-related cardiotoxicity among older breast cancer patients Surgery for widely disseminated breast cancer: prolonged control by excision of metastases Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer? Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer network Cardiotoxic Chemotherapy is Associated with Increased Heart Failure Risk Among Women with Breast Cancer in the Cancer Research Network Adjuvant Trastuzumab in HER2-Positive Breast Cancer Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40) Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions Outcomes of inflammatory versus noninflammatory T4 breast cancers in the age of taxanes and trastuzumab Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials Impact of BMI on clinical outcome of HER2-positive breast cancer Early identification of trastuzumab-related cardiotoxicity with speckle-tracking echocardiography The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review Fifteen-year trends in metastatic breast cancer survival in Greece Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases Trastuzumab-Resistant HER2-Driven Breast Cancer Cells Are Sensitive to Epigallocatechin-3 Gallate Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells HER 2 ( erb B-2)-targeted effects of the ϖ-3 polyunsaturated. Fatty acid α-linolenic acid (ALA; 18:3n-3) in breast cancer cells: the fat features of the Mediterranean diet as an anti-HER2 cocktail Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (HerceptinTM) in breast cancer cells with Her-2/neu oncogene amplification
TOP